APOGEE THERAPEUTICS I

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

15 May 2024 16:01:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

12 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

07 Mar 2024 18:49:51 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

05 Mar 2024 16:23:09 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

05 Mar 2024 06:10:00 By Nasdaq GlobeNewswire

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

05 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

04 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

13 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

30 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

27 Sep 2023 08:42:48 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

14 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

28 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

21 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

07 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

02 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

18 Jul 2023 16:01:00 By Nasdaq GlobeNewswire